Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:51:19.468Z.
Calculation as of: 2026-10-06T15:51:19.468Z.
Quote observation: 2026-10-06T15:50:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b2d28e84da0c930e75004ae600b803967d1975629f72cad3bf33ad83c9831f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Eikon Therapeutics, Inc. Common Stock
Market Cap
$415.78M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $415.78M | N/A | N/A | N/A | N/A |
| Neurogene Inc. (NGNE)vs › | $414.18M | N/A | 482.17 | 482.17 | 482.17 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.14M | N/A | 2.08 | 10.37 | 10.37 |
| Shoulder Innovations, Inc. (SI)vs › | $409.58M | 6.82 | 6.84 | 6.99 | 6.99 |
| Prothena Corporation plc (PRTA)vs › | $422.75M | 7.75 | 32.56 | 19.45 | 53.61 |
| Carlsmed, Inc. (CARL)vs › | $404.24M | 6.39 | 4.96 | 4.96 | 4.96 |
| Myriad Genetics, Inc. (MYGN)vs › | $406.60M | 0.50 | 0.60 | 1.42 | 1.98 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $395.93M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $435.92M | 0.57 | 0.42 | 0.50 | 0.63 |
| Editas Medicine, Inc. (EDIT)vs › | $438.18M | 9.32 | 6.16 | 8.52 | 20.03 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
